• Sinovac Biotech posted a net loss of $198.84 million, swinging from a profit in 2024.
• Sales rose 6.82% to $386.01 million, driven by higher varicella and influenza demand from international customers.
• Operating loss widened to $490.13 million, despite gross margin rising 6.8 percentage points to 67.9%.
• Other income fell 60.46% to $208.6 million, reflecting lower investment income and a net foreign exchange loss of $109.8 million.
• Cash and cash equivalents increased to $488.2 million, while net cash used in operating activities widened to $512.18 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-258534), on June 05, 2026, and is solely responsible for the information contained therein.